Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Feb 28;13(8):1208-13.
doi: 10.3748/wjg.v13.i8.1208.

Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis

Li-Cheng Dai  1 , Xiang Wang, Xing Yao, Yong-Liang Lu, Jin-Liang Ping, Jian-Fang He
Affiliations

Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis

Li-Cheng Dai et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the effect of antisense oligonucleotide targeting midkine (MK-AS) on angiogenesis in chick chorioallantoic membrane (CAM) and in situ human hepatocellular carcinoma (HCC).

Methods: An in situ human hepatocellular carcinoma (HCC) model and CAM assay were used in this experiment. The effect of MK-AS on angiogenesis was evaluated by cell proliferation assay and hematoxylin-eosin (HE) staining.

Results: MK-AS significantly inhibited human umbilical vein endothelial cells (HUVEC) and in situ human HCC growth. At the same time, MK-AS suppressed the angiogenesis both in human hepatocellular carcinoma cell line (HEPG2)-induced CAM and in situ human HCC tissues.

Conclusion: MK-AS is an effective antiangiogenesis agent in vivo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
RT-PCR (A) and Western-blotting analysis (B) of MK expression in human umbilical vein endothelial cells (HUVEC) after transfection with 0.4 μmol/L MK-AS (lane 4), MK-SEN (lane 3), Lipofectin alone (lane 2) for 24 h. Lane 1 represents cells without transfection. GAPDH and β-actin were used as control respectively.
Figure 2
Figure 2
Effect of MK on growth of HUVEC. Cells after transfection with 0.4 μmol/L MK-AS or MK-SEN for 24 h were analyzed by MTS assay. Data were expressed as mean ± SD from four independent experiments.
Figure 3
Figure 3
Angiogenesis in normal chick CAM (A), HepG2-induced CAM (B), and HepG2-induced CAM treated with 0.4 μmol/L MK-AS (C). Chick CAM assays were used to assess the impact of MK-AS on angiogenesis in vivo.
Figure 4
Figure 4
Immunohistochemical analysis of HCC xenograft angiogenesis after treatment with MK-SEN (A), 25 mg/kg of MK-AS per day (B), 50 mg/kg of MK-AS per day (C), and 100 mg/kg of MK-AS per day (D). Representative views of anti-CD34 antibody-stained vascular endothelium (brown) (х 200).
Figure 5
Figure 5
Tumors resected from mice at the experimental end point. Resected tumors were sectioned and stained as described in the text. Microvessel densities (MVD) were determined by counting CD34-positive endothelial cells in the sections and presented as mean ± SE positive cells/field from the three “hot-spot” fields. aP < 0.05, bP < 0.01 vs control group.
See this image and copyright information in PMC

References

    1. Folkman J, Tumor angiogenesis. In: Mendelsohn J, Howley P, Liotta LA, and Israel M, editors. The Molecular Basis of Cancer. Philadelphia: Saunders WB; 1995. p. 206–232.
    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. - PubMed
    1. Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 1998;58:1298–1304. - PubMed
    1. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003;47:149–161. - PubMed
    1. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285. - PubMed

Publication types